CGM 097
Alternative Names: CGM-097; NVP-CGM097Latest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Novartis
- Developer Novartis Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-mdm2 inhibitors; Tumour suppressor protein p53 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in France (PO)
- 28 Aug 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Germany (PO)
- 28 Aug 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Singapore (PO)